Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot Password? Reset your password

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login (Shibboleth)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Table of Contents
Vol. 28, No. 3, 2011
Issue release date: November 2011
Section title: Review
Cell Physiol Biochem 2011;28:571–578

Pendrin Function in Airway Epithelia

Nofziger C.1 · Dossena S.1 · Suzuki S.2 · Izuhara K.2 · Paulmichl M.1
1Institute of Pharmacology and Toxicology, Paracelsus Medical University, Salzburg,2Department of Biomolecular Sciences, Saga Medical School, Saga
email Corresponding Author

Markus Paulmichl, Institute of Pharmacology and Toxicology

Paracelsus Medical University, Salzburg (Austria)

E-Mail markus.paulmichl@pmu.ac.at

or Kenji Izuhara, Department of Biomolecular Sciences, Saga Medical School

Nabeshima, Saga, 849-8501 (Japan), E-Mail kizuhara@cc.saga-u.ac.jp

Do you have an account?

Login Information

Contact Information

I have read the Karger Terms and Conditions and agree.


The expression and function of the anion exchanger pendrin (SLC26A4) was thought to be limited mainly to the inner ear, kidney and thyroid. Recent data indicates that pendrin is also expressed in the bronchial epithelium following exposure to the TH2-type cytokines, interleukin (IL)-4 and IL-13. Expression of the transporter is also upregulated in bronchial asthma and chronic obstructive pulmonary disease. Both diseases involve respiratory inflammation leading to tissue destruction/remodeling and decreased airway function, and data so far indicate that increased pendrin expression and/or activity might contribute to their pathogenesis. In this review, we summarize data that have emerged within the past years aimed at revealing the role for pendrin in the airway epithelia.

© 2011 S. Karger AG, Basel

Article / Publication Details

First-Page Preview
Abstract of Review

Accepted: September 27, 2011
Published online: November 18, 2011
Issue release date: November 2011

ISSN: 1015-8987 (Print)
eISSN: 1421-9778 (Online)

For additional information: http://www.karger.com/CPB

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.